PL3254702T3 - Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych - Google Patents

Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych

Info

Publication number
PL3254702T3
PL3254702T3 PL15874441.7T PL15874441T PL3254702T3 PL 3254702 T3 PL3254702 T3 PL 3254702T3 PL 15874441 T PL15874441 T PL 15874441T PL 3254702 T3 PL3254702 T3 PL 3254702T3
Authority
PL
Poland
Prior art keywords
xbp1s
optimisation
aav
virus
learning
Prior art date
Application number
PL15874441.7T
Other languages
English (en)
Inventor
Claudio Andrés HETZ FLORES
Gabriela Raquel Elena MARTINEZ BRAVO
Original Assignee
Universidad De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Chile filed Critical Universidad De Chile
Publication of PL3254702T3 publication Critical patent/PL3254702T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL15874441.7T 2014-12-30 2015-12-24 Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych PL3254702T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2014003590A CL2014003590A1 (es) 2014-12-30 2014-12-30 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
PCT/CL2015/000069 WO2016106458A1 (es) 2014-12-30 2015-12-24 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje

Publications (1)

Publication Number Publication Date
PL3254702T3 true PL3254702T3 (pl) 2023-09-11

Family

ID=56283749

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15874441.7T PL3254702T3 (pl) 2014-12-30 2015-12-24 Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych

Country Status (6)

Country Link
US (2) US11400166B2 (pl)
EP (1) EP3254702B1 (pl)
CL (1) CL2014003590A1 (pl)
ES (1) ES2949828T3 (pl)
PL (1) PL3254702T3 (pl)
WO (1) WO2016106458A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2015003024A1 (es) * 2015-10-09 2016-05-13 Univ Chile Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica.
CL2015003242A1 (es) 2015-11-04 2016-10-14 Univ Chile Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras.
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
US20220184175A1 (en) * 2019-02-01 2022-06-16 Universidad De Chile Treatment of aging or age-related disorders using xbp1
TW202115126A (zh) 2019-06-11 2021-04-16 美商舒爾人類基因療法公司 用於治療血漿激肽釋放酶失調所介導之疾病的抗體腺相關病毒載體遞送
EP3999647A1 (en) * 2019-07-18 2022-05-25 Lysogene Compositions and methods for the treatment of sanfilippo disease and other disorders
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
WO2023143435A1 (zh) * 2022-01-29 2023-08-03 上海日馨医药科技股份有限公司 表达tpk的重组病毒及其治疗阿尔茨海默病的用途
CN115779083B (zh) * 2022-08-05 2024-04-02 河南省精神病医院(新乡医学院第二附属医院) 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090836B2 (en) 2002-06-21 2006-08-15 Institut Pasteur Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal
WO2009034127A1 (en) 2007-09-12 2009-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the cyp46a1 gene for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
WO2016106458A8 (es) 2021-12-23
ES2949828T3 (es) 2023-10-03
US20170360961A1 (en) 2017-12-21
EP3254702A1 (en) 2017-12-13
CL2014003590A1 (es) 2015-07-10
US20210060178A1 (en) 2021-03-04
US11400166B2 (en) 2022-08-02
WO2016106458A1 (es) 2016-07-07
EP3254702B1 (en) 2023-05-10
EP3254702A4 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
PL3254702T3 (pl) Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych
HK1257310A1 (zh) 抗-cd47抗體及使用方法
IL272463A (en) Nucleic acid molecules and their uses
ZA201606763B (en) Aav vectors for retinal and cns gene therapy
IL251468A0 (en) aav-based gene therapy
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
EP3157573A4 (en) Alternative nucleic acid molecules and uses thereof
EP3157572A4 (en) Alternative nucleic acid molecules and uses thereof
EP3154391A4 (en) Hair conditioning treatment apparatus and method
ZA201605760B (en) Immobilized proteins and use thereof
IL273976A (en) Methods and materials for NT-3 gene therapy
HK1257519A1 (zh) 用於 galgt2 基因治療的方法和物質
EP3238281A4 (en) Resistive memory cells and precursors thereof, methods of making the same, and devices including the same
PT3131577T (pt) Células hospedeiras modificadas e suas utilizações
HK1220015A1 (zh) 基因測序儀的控制裝置、方法和基因測序儀
IL253967B (en) Resistant herbicide protein, gene encoded and compatible use
ZA202000152B (en) Means and methods for aav gene therapy in humans
ZA201705395B (en) Herbicide-resistant protein, encoding gene and use thereof
EP3121282A4 (en) Novel samdori-2 gene and use thereof
IL267589A (en) adam9 binding molecules and methods for their use
HK1214623A1 (zh) 標簽、 引物及其應用
DK3227430T3 (da) Svampeværtsstammer, dna-konstruktioner og fremgangsmåder til anvendelse
HK1253878A1 (zh) 小麥過敏原結合核酸分子及其用途
GB201622225D0 (en) Modified host cells and uses thereof